9.2 Pathophysiology of Shock & Perioperative Fluid Therapy

9.2 Pathophysiology of Shock & Perioperative Fluid Therapy

UPSC CMS High-Yield Core Focus: Comprehensive mastery of shock classification, hemodynamic parameters (CO, SVR, CVP, PCWP), ATLS classification of hemorrhagic shock, perioperative fluid distribution, the 4-2-1 maintenance rule, crystalloid choices, and vasopressor/inotrope pharmacology.

---

1. Pathophysiology & Hemodynamic Classification of Shock

Shock is a state of systemic tissue hypoperfusion resulting from an acute imbalance between systemic oxygen delivery ($DO_2$) and cellular oxygen demand ($VO_2$). Cellular hypoxia shifts metabolism from aerobic respiration to anaerobic glycolysis, leading to accumulation of systemic lactic acid, ATP depletion, cell membrane pump failure, intracellular edema, organ collapse, and death.

$\text{Oxygen Delivery } (DO_2) = \text{Cardiac Output } (CO) \times \text{Arterial Oxygen Content } (CaO_2)$ $\text{Cardiac Output } (CO) = \text{Heart Rate } (HR) \times \text{Stroke Volume } (SV)$

Hemodynamic Profiles of Shock Types

Critical Clinical Nuance: Neurogenic shock is uniquely characterized by hypotension combined with bradycardia (due to loss of sympathetic cardiac accelerator fibers T1–T4 and unopposed vagal tone) and warm, dry peripheries.

---

2. ATLS Classification of Hemorrhagic Shock

The Advanced Trauma Life Support (ATLS) guidelines classify hemorrhagic shock into four categories based on blood loss in a 70 kg adult (total blood volume ~5,000 mL or 70 mL/kg).

Key Exam Pearl: In Class II hemorrhagic shock, systolic blood pressure remains normal due to compensatory arterial vasoconstriction, but the pulse pressure narrows (diastolic pressure rises toward systolic). Explicit drop in systolic blood pressure defines Class III shock.

---

3. Perioperative Fluid Therapy & Distribution

Total Body Water (TBW) Distribution

• Total Body Water constitutes 60% of body weight in adult males (50% in females).
• Intracellular Fluid (ICF): 2/3 of TBW (~40% of body weight).
• Extracellular Fluid (ECF): 1/3 of TBW (~20% of body weight), further subdivided into:
  • Interstitial Fluid: 3/4 of ECF (~15% of body weight).
  • Intravascular Plasma: 1/4 of ECF (~5% of body weight).

Maintenance Fluid Requirements: The 4-2-1 Rule

For ongoing hourly maintenance intravenous fluids in fasting surgical patients:

• First 10 kg of body weight: $4 mL/kg/hour$ ($10 × 4 = 40 mL/h$)
• Second 10 kg of body weight (11–20 kg): $2 mL/kg/hour$ ($10 × 2 = 20 mL/h$)
• Each additional kg above 20 kg: $1 mL/kg/hour$

Calculation Example for a 70 kg Adult:

$$\text{Hourly Rate} = (10\text{ kg} \times 4) + (10\text{ kg} \times 2) + (50\text{ kg} \times 1) = 40 + 20 + 50 = \textbf{110 mL/hour}$$

Daily Electrolyte Requirements

• Water: 25 – 30 mL/kg/day
• Sodium ($Na^+$): 1 – 2 mmol/kg/day
• Potassium ($K^+$): 1 mmol/kg/day
• Glucose: 50 – 100 g/day (prevents starvation ketosis and limits protein breakdown)

---

4. Intravenous Fluid Formulations: Crystalloids vs. Colloids

---

5. Vasopressors and Inotropes in Shock Management

When fluid resuscitation fails to achieve adequate arterial perfusion (Target Mean Arterial Pressure $\ge 65 mmHg$), vasoactive medications are initiated.

$$\text{MAP} = \text{Diastolic BP} + \frac{1}{3}(\text{Systolic BP} - \text{Diastolic BP})$$

Pharmacology of Key Vasoactive Agents

1. Norepinephrine:

   • Mechanism: Potent $\alpha_1$-receptor agonist with mild $\beta_1$-inotropic activity.
   • Effects: Marked vasoconstriction elevating SVR and blood pressure with minimal change in heart rate.
   • Clinical Role: First-line vasopressor in Septic Shock and vasodilatory shock.

2. Epinephrine:

   • Mechanism: Potent $\alpha_1$, $\beta_1$, and $\beta_2$ agonist.
   • Effects: Increases heart rate, cardiac contractility, and systemic vascular resistance.
   • Clinical Role: First-line drug for Anaphylactic Shock (0.5 mg IM 1:1,000 dilution in adults); second-line agent for refractory septic shock or cardiac arrest.

3. Dopamine:

   • Mechanism: Dose-dependent receptor affinity:
     • Low Dose ($1–5\ \mu\text{g/kg/min}$): $D_1$ dopaminergic receptors $\rightarrow$ renal/splanchnic vasodilation.
     • Medium Dose ($5–10\ \mu\text{g/kg/min}$): $\beta_1$ adrenergic $\rightarrow$ increased cardiac contractility and HR.
     • High Dose ($>10\ \mu\text{g/kg/min}$): $\alpha_1$ adrenergic $\rightarrow$ systemic vasoconstriction.
   • Clinical Role: Largely replaced by norepinephrine due to higher incidence of tachyarrhythmias.

4. Dobutamine:

   • Mechanism: Selective $\beta_1$-receptor agonist with mild $\beta_2$-vasodilation.
   • Effects: Potent inotropy (increases stroke volume) and chronotropy with mild reduction in SVR (inodilator).
   • Clinical Role: First-line inotropic agent in Cardiogenic Shock with low cardiac output and adequate blood pressure.

5. Vasopressin (Antidiuretic Hormone):

   • Mechanism: Direct stimulation of vascular smooth muscle $V_1$ receptors.
   • Effects: Potent vasoconstriction independent of adrenergic receptors.
   • Clinical Role: Fixed-dose adjunct ($0.03 units/min$) to norepinephrine in refractory septic shock to restore vascular tone.